NEW YORK (TheStreet) -- Shares of AbbVie rose 0.72% to $61.64 in afternoon trading Tuesday after a pair of bullish comments from two analysts. Deustche Bank spots a potential catalyst in AbbVie's partnership with Galapagos on a treatment for rheumatoid arthritis: AbbVie & Galapagos are expected to release data for their JAK-1, Filgotinib in mid-April (DARWIN-1) in Rheumatoid Arthritis (RA).